Cancer Drug Resistance Journal Announces Partnership with EACR-Boehringer Ingelheim Conference on MAP Kinase Pathway Regulation

The journal Cancer Drug Resistance is pleased to announce a media partnership with the European Association for Cancer Research (EACR) and Boehringer Ingelheim for the upcoming EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway. This virtual event, accessible worldwide, is scheduled to take place on 11-12 February 2025.

This conference, now in its second edition, is organized jointly by EACR and Boehringer Ingelheim. It will delve into both the basic and clinical facets of Mitogen-Activated Protein Kinase (MAPK) pathway regulation, a pathway frequently mutated in human cancers. The program is designed to present groundbreaking insights into the mechanisms of new-generation pan-RAS inhibitors and rational combination therapies.

Targeted at researchers from both academia and industry, the conference will explore the role of the MAPK pathway in genetically targeted and immune-based anticancer therapies. Additionally, it will cover mechanistic aspects of gene regulation, target validation, and drug development, as well as emerging translational and clinical opportunities offered by small molecule inhibitors.

For more details and to register, please visit the official website:
https://eacr.org/conference/boehringer-ingelheim2025?utm_source=CDR&utm_medium=web&utm_campaign=vMAP25&utm_content=affiliate

This collaboration underscores Cancer Drug Resistance journal's commitment to advancing cancer research and fostering a deeper understanding of drug resistance mechanisms, further solidifying its position as a leading publication in the oncology community.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Cancer Drug Resistance